Related Experiment Video
Updated: May 29, 2026
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
Therapeutic potential of PARP inhibitors for metastatic breast cancer
Sheeba Irshad1, Alan Ashworth, Andrew Tutt
1Breakthrough Breast Cancer Unit Research Oncology, 3rd Floor Bermondsey Wing, Guy's Hospital Campus, Kings College London School of Medicine, London, SE1 9RT, UK.
Abstract:
Increasing understanding of the cellular aberrations inherent to cancer cells has allowed the development of therapies to target biological pathways, an important step towards individualization of breast cancer therapy. The clinical development of poly(ADP-ribose) polymerase (PARP) inhibitors, with their novel and selective mechanism of action, are an example of this strategy. PARP plays a key role in DNA repair mechanisms, particularly the base excision repair pathway. Initially developed as inhibitors able to enhance the cytotoxicity of radiation and certain DNA-damaging agents, they have more recently been shown to have single-agent activity in certain tumors. Inhibition of PARP in a DNA repair-defective tumor can lead to gross genomic instability and cell death by exploiting the paradigm of synthetic lethality. Several studies have evaluated the role of PARP inhibitors for treatment of breast cancer, particularly in the context of BRCA-mutated and triple-negative breast cancers. In addition, inhibition of PARPs repair functions for chemotherapy-induced DNA lesions has been shown to potentiate the effect of some chemotherapy regimens. This article discusses the current understanding of PARP inhibition as a treatment for metastatic breast cancer, evidence from clinical trials and addresses its future implications.
Insights
Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for treating breast cancer, especially BRCA-mutated and triple-negative types. These drugs exploit DNA repair defects for cancer cell death, enhancing chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Advances in understanding cancer cell biology enable targeted therapies for personalized breast cancer treatment.
- Poly(ADP-ribose) polymerase (PARP) inhibitors represent a novel therapeutic strategy targeting DNA repair pathways.
Purpose of the Study:
- To discuss the current understanding of PARP inhibition in metastatic breast cancer treatment.
- To review clinical trial evidence for PARP inhibitors in breast cancer.
- To explore the future implications of PARP inhibition in breast cancer therapy.
Main Methods:
- Review of scientific literature and clinical trial data on PARP inhibitors.
- Analysis of PARP's role in DNA repair, specifically base excision repair.
- Exploration of synthetic lethality principles in DNA repair-defective tumors.
Main Results:
- PARP inhibitors demonstrate single-agent activity in certain tumors.
- Inhibition of PARP in DNA repair-defective tumors leads to genomic instability and cell death.
- PARP inhibitors show efficacy in BRCA-mutated and triple-negative breast cancers.
- PARP inhibition potentiates chemotherapy by targeting chemotherapy-induced DNA lesions.
Conclusions:
- PARP inhibitors are a significant development in targeted breast cancer therapy.
- Clinical trials support the use of PARP inhibitors, particularly in specific breast cancer subtypes.
- PARP inhibition holds considerable promise for future metastatic breast cancer treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
02:34Inhibition of Cdk Activity